Metabolic Solutions Development
BioSystem Development, LLC Mithridion, Inc.
CellCura Inc NeoChord, Inc.
Cellectar, Inc. Nerites Corporation
Cellular Dynamics International, Inc. NewLink Genetics Corporation
Checkpoint Surgical Novian Health
Compact Particle Acceleration Corp. OrthoData Inc.
CytoPherx, Inc. Phoenix Nuclear Labs
Dgimed Ortho, Inc. Quintessence Biosciences, Inc.
Echometrix Rapid Diagnostek, Inc.
EraGen Biosciences, Inc. Ratio, Inc.
Flex Biomedical Siloam Biosciences, Inc.
FluGen Inc. TheraVasc, LLC
Galera Therapeutics, LLC Vestaron Corporation
This year's conference sponsors have lent support beyond their financial commitment to help secure quality speakers and presenting companies. 2009's sponsors include: Forward Wisconsin, Grant Thornton, Michael Best & Friedrich, LLP, The Domann Organization, B.C. Ziegler & Company, and Whyte Hirschboeck Dudek S.C.
The 2009 exhibitors include: Baird Venture Partners, Covance, Silicon Valley Bank, StatKing Consulting, Thrive, State of Wisconsin Investment Board, University Research Park, UW - Madison Office of Corporate Relations, Venture Investors, LLC, WARF, and Wisconsin Department of Financial Institutions.
Strategic Alliances include: MVCA, LifeScience Alley, MRUN, Bioforward, and iBio.
To learn more about the event program and to register, please visit: www.midamericahealthcareforum.com.
About International Business Forum, Inc.
IBF-International Business Forum, Inc. is a leading presenter Page: 1 2 3 4 Related medicine technology :1
. invivodata Recognized as One of Pittsburghs Fastest Growing Private Companies2
. BIOCOMs 4th Annual DeviceFest Honors Companies3
. R&D Spending by U.S. Biopharmaceutical Companies Reaches Record Levels in 2008 Despite Economic Challenges4
. Magellan Biosciences Companies to Feature Automated Products and New Tests for MRSA at the American Society for Microbiology Meeting, Booth 7435
. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies6
. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies7
. Pharmaceutical Companies Lead Fight Against Staph and Other Infectious Diseases8
. NuVasive to Present at the JMP Securities Healthcare Focus Conference9
. Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects10
. OPAXIO(TM) Phase II Trial in Esophageal Cancer to be Presented in Proffered Session at the International Society of Gastrointestinal Oncology Annual Meeting11
. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress